Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Score, Valuation & Financial Research
Tonix Pharmaceuticals Holding Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for TNXP
Tonix Pharmaceuticals Holding Corp. currently has a Wall Street Score of 34/100. The stored market price is $11.62. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Tonix Pharmaceuticals Holding Corp. does
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as
TNXP financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $11.62
- Market capitalization:
- $185.2M
- Revenue:
- $17.6M
- Net income:
- $-147.4M
- Free cash flow:
- $-103.2M
- Cash:
- $185.5M
- Total debt:
- $1.3M
- EPS:
- -14.57
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $-103.2M, showing cash burn in the current stored period.
- The balance sheet shows $185.5M of cash versus $1.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TNXP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.